Q-omics provides the consensus-scored TMEM134 profile across patient tissues and cancer cell-line models. TMEM134 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM134 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TMEM134 RNA expression shows 18,978 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where TMEM134 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM134 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM134 survival associations across molecular data types. TMEM134 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM134 RNA expression–survival associations across cancer types. High TMEM134 expression shows unfavorable associations in ACC and KICH, but favorable associations in COAD, BLCA, THCA and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM134 RNA expression.
This table summarizes TMEM134 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM134. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM134 shows higher tumor expression in KIRC, THCA, LIHC, LUSC, BLCA and LUAD. The KIRC box plot shows higher TMEM134 RNA expression in tumor versus normal tissue (log2 FC = +0.904, t-test p < 0.001).
This table shows molecular features associated with TMEM134 in patient tissues and cancer cell lines. In patient samples, TMEM134 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM134 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
